Pancreas Cancer Clinical Trial
Official title:
Prospective Cohort Study for Identifying Factors Predicting Clinical Outcomes of Pancreatic Cancer Patients Treated With Proton Beam Therapy
Pancreatic cancer is one of the few cancers whose survival rate has not improved
significantly due to high local recurrence and systemic metastasis despite advances in
diagnosis and treatment over the past 40 years. And currently pancreatic cancer is the fifth
leading cause of cancer-related death in Korea. For this reason, various anti-cancer
therapies and radiotherapy have been tested to improve survival.
Due to recent advances in radiotherapy technology, proton beam therapy (PBT) is a promising
treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal
tissue while maximizing radiation to tumor tissues due to the distinct physical properties of
proton beam. Low toxicity have been reported. In addition, retrospective analysis of
pancreatic cancer patients (n=37) who performed proton therapy (PBT) from June 2013 to July
2016 showed promising therapeutic performance and less toxicity (survival rate, 19.3 months;
Grade ≥ 3 Toxicity, 0%). In addition, gene polymorphisms of several genes (CD44, CD166, XAF1,
MMP9, MUC1/4, SMAD7, SMAD4 (DPC), RRM1, ERCC1, HER2, etc.) in pancreatic cancer have been
reported to be associated with recurrence and prognosis.
Pancreatic cancer is one of the few cancers whose survival rate has not improved
significantly due to high local recurrence and systemic metastasis despite advances in
diagnosis and treatment over the past 40 years. And currently pancreatic cancer is the fifth
leading cause of cancer-related death in Korea. For this reason, various anti-cancer
therapies and radiotherapy have been tested to improve survival.
Due to recent advances in radiotherapy technology, proton beam therapy (PBT) is a promising
treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal
tissue while maximizing radiation to tumor tissues due to the distinct physical properties of
proton beam. Low toxicity have been reported. In addition, retrospective analysis of
pancreatic cancer patients (n=37) who performed proton therapy (PBT) from June 2013 to July
2016 showed promising therapeutic performance and less toxicity (survival rate, 19.3 months;
Grade ≥ 3 Toxicity, 0%). In addition, gene polymorphisms of several genes (CD44, CD166, XAF1,
MMP9, MUC1/4, SMAD7, SMAD4 (DPC), RRM1, ERCC1, HER2, etc.) in pancreatic cancer have been
reported to be associated with recurrence and prognosis. Therefore, in this study, a
prospective cohort of pancreatic cancer patients treated with proton beam therapy was
established to analyze local control, survival, recurrence, toxicity, proton treatment plan
information, gene expression information to analyze local control (LC), overall survival
(OS), recurrence-free surival (RFS), and factors predicting treatment-related toxicity.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05435053 -
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Recruiting |
NCT06065891 -
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05048524 -
Peri-operative SLOG for Localized Pancreatic Cancer
|
Phase 2 | |
| Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Recruiting |
NCT05501379 -
Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
|
||
| Recruiting |
NCT04851106 -
Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
|
||
| Not yet recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT01411072 -
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
|
N/A | |
| Active, not recruiting |
NCT01448668 -
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
|
N/A | |
| Completed |
NCT01155882 -
Registry Study - Whipple at the Splenic Artery
|
||
| Recruiting |
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
||
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 | |
| Withdrawn |
NCT05702385 -
Clinical Utility Study for Exo-PDAC
|
N/A |